 Zacks Investment Research upgraded shares of Allakos NASDAQ:ALLK from a strong sell rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports. According to Zacks, Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos ... 